98 related articles for article (PubMed ID: 11586375)
1. The science of health technology assessment: the safety perspective.
Shear NH
Can J Clin Pharmacol; 2001; 8 Suppl A():24A-28A. PubMed ID: 11586375
[TBL] [Abstract][Full Text] [Related]
2. The science of health technology assessment--the economic perspective.
Menon D
Can J Clin Pharmacol; 2001; 8 Suppl A():17A-20A. PubMed ID: 11586373
[TBL] [Abstract][Full Text] [Related]
3. Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC; Smith MA; Gelin MN; Heathcote SC
Can J Clin Pharmacol; 2007; 14(1):e45-57. PubMed ID: 17297195
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
Benjamin DM; Pendrak RF
J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
[TBL] [Abstract][Full Text] [Related]
6. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
7. Making the most of spontaneous adverse drug reaction reporting.
Waller PC
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):320-3. PubMed ID: 16611209
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
9. [Adverse drug reactions definitions and terminology].
Rabinovitz H; Berkowitch M; Golik A; Shani S
Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
[TBL] [Abstract][Full Text] [Related]
10. Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safety.
Wong E; Carleton BC; Wright DF; Smith MA; Verbeek L; Hildebrand CA; Stannard P; Vaillancourt R; Elliot-Miller P; Ross CJ; Hayden MR
Stud Health Technol Inform; 2009; 143():209-14. PubMed ID: 19380938
[TBL] [Abstract][Full Text] [Related]
11. Nonimmunologic adverse drug reactions. How to recognize and categorize some common reactions.
Bernstein JA
Postgrad Med; 1995 Jul; 98(1):120-2, 125-6. PubMed ID: 7603941
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions in childhood: a review of prospective studies and safety alerts.
Clavenna A; Bonati M
Arch Dis Child; 2009 Sep; 94(9):724-8. PubMed ID: 19531524
[TBL] [Abstract][Full Text] [Related]
13. Regulatory agencies, pharmaceutical information and the Internet: a European perspective.
Bauschke R
Health Policy; 2012 Jan; 104(1):12-8. PubMed ID: 22101089
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical industry overview: optimal drug therapy.
Blake P
Can J Clin Pharmacol; 2001; 8 Suppl A():48A-52A. PubMed ID: 11586380
[TBL] [Abstract][Full Text] [Related]
15. The science of health technology assessment--clinical effectiveness of therapeutic interventions.
LeLorier J
Can J Clin Pharmacol; 2001; 8 Suppl A():21A-23A. PubMed ID: 11586374
[TBL] [Abstract][Full Text] [Related]
16. [Self-assessment by physicians concerning their management of drug risks. Information sources, risk evaluation, problems and recommendations for improvements].
Kemmnitz W
Z Arztl Fortbild Qualitatssich; 1998 Sep; 92(7):509-12. PubMed ID: 9842698
[TBL] [Abstract][Full Text] [Related]
17. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment of drugs, biologics and therapeutic devices: present and future issues.
Centers for Education and Research on Therapeutics Risk Assessment Workshop
Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):653-62. PubMed ID: 14762981
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions among children over a 10-year period.
Le J; Nguyen T; Law AV; Hodding J
Pediatrics; 2006 Aug; 118(2):555-62. PubMed ID: 16882807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
